These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15996946)

  • 21. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
    Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
    J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
    Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
    Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review. Clinical pharmacokinetics of bortezomib.
    Levêque D; Carvalho MC; Maloisel F
    In Vivo; 2007; 21(2):273-8. PubMed ID: 17436576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety and efficacy of bortezomib in relapsed multiple myeloma.
    Jagannath S
    Clin Adv Hematol Oncol; 2006 May; 4(5):2-3; discussion 8; suppl 13. PubMed ID: 16830423
    [No Abstract]   [Full Text] [Related]  

  • 25. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
    Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
    Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
    Richardson PG; Mitsiades C; Ghobrial I; Anderson K
    Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
    Qayum A; Aleem A; Al Diab AR; Niaz F; Al Momen AK
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):63-8. PubMed ID: 20061695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanding role of bortezomib in multiple myeloma: nursing implications.
    Colson K; Doss DS; Swift R; Tariman J
    Cancer Nurs; 2008; 31(3):239-49. PubMed ID: 18453881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of bortezomib for the treatment of previously untreated multiple myeloma.
    Mateos MV
    Expert Rev Hematol; 2008 Oct; 1(1):17-28. PubMed ID: 21083004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
    Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
    Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
    [No Abstract]   [Full Text] [Related]  

  • 32. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.
    Kim SJ; Kim K; Do YR; Bae SH; Yang DH; Lee JJ
    Jpn J Clin Oncol; 2011 Mar; 41(3):353-7. PubMed ID: 20947927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.
    Walter-Croneck A; Grzasko N; Soroka-Wojtaszko M; Jurczyszyn A; Torosian T; Rymko M; Nowicki A; Druzd-Sitek A; Lech-Maranda E; Madro E; Zielinska P; Grygoruk-Wisniowska I; Blonska D; Usnarska-Zubkiewicz L; Potoczek S; Iskierka E; Masternak A; Holojda J; Dawidowska D; Gawron L; Barchnicka A; Olszewska-Szopa M; Rybicka M; Gontarska A; Jachalska A; Rzepecki P; Subocz E; Boguradzki P; Charlinski G; Dzierzak-Mietla M; Wisniewska-Piaty K; Swistek W; Kopacz A; Blajer-Olszewska B; Swiderska A; Dmoszynska A
    Leuk Res; 2014 Jul; 38(7):788-94. PubMed ID: 24862794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].
    Spicka I; Hájek R; Vytrasová M; Maisnar V; Gregora E; Schutzova M; Straub J; Scudla V; Adam Z; Klener P
    Cas Lek Cesk; 2005; 144(9):636, 638-40. PubMed ID: 16193944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 36. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
    Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
    J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology].
    Gotoh A; Ohyashiki K; Oshimi K; Usui N; Hotta T; Dan K; Ikeda Y; ;
    Rinsho Ketsueki; 2006 Dec; 47(12):1521-7. PubMed ID: 17233470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
    J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibition in multiple myeloma.
    Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
    Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib in multiple myeloma.
    Vandenbroucke JP; Kroep JR
    N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.